

Hutchison China MediTech (Chi-Med)

Acceptance of surufatinib China NDA in epNET

12 November 2019

- Chi-Med's NDA (new drug application) for surufatinib in the treatment of patients with advanced non-pancreatic neuroendocrine tumours (epNET) has been accepted for review by the China National Medical Products Administration (NMPA).
- This NDA is supported by the pivotal Phase III SANET-ep trial. Positive data was presented at ESMO 2019 (see our [October 2019 Update](#)), and showed an investigator assessed PFS of 9.2 months for surufatinib vs 3.8 months for placebo (hazard ratio = 0.334, $p < 0.0001$), as well as encouraging broad utility across epNET subtypes.
- Subject to regulatory approval in epNET, Chi-Med could launch surufatinib in as early as c 12 months, in late 2020, based on an extrapolation from the China approval timeline for fruquintinib (Elunate).
- Ahead of an approval decision, Chi-Med is building a dedicated commercial oncology organisation, which it expects will cover all relevant hospitals and clinics in China by the time of potential surufatinib launch.
- Ep-NET is surufatinib's lead indication; it is also under investigation in multiple solid tumour types in both China (Phase III SANET-p in pancreatic NET; Phase IIb/III in advanced biliary tract cancer), and the US/Europe (Phase Ib NET). Due to its dual mechanism of action surufatinib is also being studied in combination with PD-1 immunotherapies in China.
- Chi-Med retains all worldwide rights to surufatinib.

Price (US ADS) (UK share)	\$22.40 360p
Market Cap	\$2.99bn £2.40bn
Exchanges	NASDAQ AIM London
Sector	Healthcare
Company codes	HCM HCM.L
Corporate client	Yes

Company description:

Hutchison China MediTech is a Hong Kong headquartered biopharma with an established Commercial Platform in China, and a diverse pipeline of first-in-class/best-in-class selective oral tyrosine kinase inhibitors (Innovation Platform). Its pipeline, discovered in-house, is in development for the China and global oncology markets.

Trinity Delta view: Confirmation of the acceptance of the surufatinib China NDA is an important strategic step for Chi-Med. Subject to regulatory approval, Chi-Med could launch its first wholly owned oncology drug in late-2020, commercialising it through its own China Oncology commercial organisation.

Prior to an approval decision, we expect further clinical news flow related to surufatinib in NET during H120, with the interim analysis of the China SANET-p Phase III in pNET and initiation of the US/Europe registration study.

We also anticipate various other clinical, regulatory, and commercial catalysts during 2019 and 2020 that will unlock further value. The first is expected to be an imminent NRDL inclusion decision for fruquintinib (Elunate) in 3L CRC. Elunate was approved and launched in China by partner Eli Lilly in H218; NRDL inclusion should significantly boost its market penetration and future revenues.

H120 should also see the first savolitinib regulatory submission, with filing of the China NDA for MET exon 14m/del 1L NSCLC.

We currently value Chi-Med at \$5.14bn (\$38.55/ADS) or £3.95bn (£5.93/share).

Analysts

Franc Gregori

fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Mick Cooper PhD

mcooper@trinitydelta.org
+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Mick Cooper PhD CFA

mcooper@trinitydelta.org

+44 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org

+44 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org

+44 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2019 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org